Skip to content

Exploring Brain Changes in Patients with Heart Failure with Reduced Ejection Fraction During Vulnerable Period.

Exploring Brain Changes in Patients with Heart Failure with Reduced Ejection Fraction During Vulnerable Period.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0007355
Enrollment
30
Registered
2022-06-03
Start date
2022-05-19
Completion date
Unknown
Last updated
2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Koera University Guro Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patient with left ventricular ejection fraction of 40% or less on echocardiogram within 3 months. 2. Patient with sinus rhythm without atrial fibrillation. 3. Patient who have experienced worsening heart failure within 4 weeks or have been newly diagnosed with heart failure. 1) Symptoms above NYHA II 2) NT-proBNP 800 = pg/mL 4. Patient who can take a brain MRI without assistance.

Exclusion criteria

Exclusion criteria: 1. Patient who has been diagnosed with atrial fibrillation or is being treated. 2. Patient who had a stroke or cerebral hemorrhage within 3 months of participation in the study. 3. Patient who has a myocardial infarction or needs surgery or vascular intervention for coronary artery disease at the time of participation in the study. 4. Patient who are taking more than one anti-platelet drug at the time of participation in the study. (COX-1 inhibitor such as aspirin, triflusal, ADP receptor antagonists such as clopidogrel, ticlopidine, prasugrel, ticagrelor. PDE-3 inhibitor such as cilostazol, dipyridamole. serotonin receptor antagonists such as sarpogrelate.) 5. Patient who are taking anticoagulation drug or need anticoagulation (e.g. mechanical valves, moderate to severe mitral stenosis, pulmonary thromboembolism or deep vein thrombosis.) 6. Patient with terminal heart failure expected to die within 6 months 7. Patient who is a bed-ridden state or cannot take a brain MRI without help. 8. Patient who have already been diagnosed with dementia and are taking drugs such as donepezil, galantamine and rivastigmine.

Design outcomes

Primary

MeasureTime frame
cortical thickness;the number of cortical microinfarcts;number of lacunes;white matter hyperintensity severity;the number of microbleeds

Secondary

MeasureTime frame
Mini-Mental State Examination, MMSE;Seoul Verbal learning Test;Digit Span Test;Stroop-CR;Phonemic Controlled Oral Word Association Test;Trail Making Test-B, TMT-B;Digit Symbol Coding, DSC;Korea version of Boston Naming Test, K-BNT;Semantic Controlled Oral Word Association Test;Rey–Osterrieth Complex Figure Copy Test

Countries

Korea, Republic of

Contacts

Public ContactSu Jin Park

Koera University Guro Hospital

kumc3018@naver.com+82-2-2626-3022

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026